INS and breast carcinoma: In cohorts of female breast cancer survivors with assessments of biomarkers up to 1 year postsurgery, higher levels of fasting insulin, compared to lower levels, have been associated with increased recurrences,29, 30, 31 cancer‐specific deaths,32 and all‐cause mortality.30